Determination of stereospecificity of benzo[a]pyrene diolepoxide-DNA antisera with site-specifically modified oligonucleotides

T. M. Hsu, T. M. Liu, S. Amin, Nicholas Geacintov, R. M. Santella

Research output: Contribution to journalArticle

Abstract

Antisera developed against benzo[a]pyrene diolepoxide (BPDE)-DNA adducts are sensitive tools for detection of DNA adducts in human samples. All antisera currently used for biomonitoring studies were produced against DNA or guanosine modified with racemic anti-BPDE. Using a non-competitive enzyme-linked immunosorbent assay (ELISA). Venkatachalam and Wani recently tested polyclonal and monoclonal (5D2) antisera for cross-reactivity against oligonucleotides containing (+)- and (-)-trans-anti-BPDE-N 2-guanine or N 6-adenine adducts and showed different stereospecificity for the two antisera. Because of the importance of antiserum specificity in human biomonitoring studies, we have tested several monoclonal (Mab 5D11 and 5D2) and polyclonal (Pab No 29) antisera developed against racemic anti-BPDE-DNA adducts, and Mab 8E11 developed against anti-BPDE-guanosine adducts. Stereoisomeric anti-BPDE-modified oligonucleotide adducts in the sequence 5'-d(CC-AT-CG(*)CTACC)-3' where G(*) = anti-BPDE-N 2-dG with (+)-trans, (-)-trans, (+)-cis and (-)-cis adduct stereochemistry at the C10 position of anti-BPDE were tested by competitive ELISA. Two structurally related 5-methylchrysene diolepoxide adducts with G(*) = (+)- and (-)-trans-anti-5-MeCDE-N 2-dG in the same oligonucleotide were also tested. While Mab5D2 had the highest affinity for the (-)-trans-anti-BPDE-modified oligomer, Mab 5D11 and 8E11 and Pab No 29 recognized the(+)-trans-anti-BPDE-modified oligomer better than the (-)-trans-anti-BPDE modified oligomer. Mab 5D11 and Pab No 29 recognized racemic anti-BPDE-modified DNA adducts better than trans-anti-BPDE-modifled oligonucleotides; however, Mab 8E11 showed similar sensitivity to racemic anti-BPDE-DNA adducts and (+)-and (-)-trans-anti-BPDE-modified oligomers. All antisera exhibited lower reactivities with both 5-MeCDE modified oligomers. Because of their sensitive detection of (+)-trans-anti-BPDE-dG adducts, the primary adduct produced in vivo, Mab 8E11 and 5D11 and Pab No 29 are appropriate for measurement of most adducts formed in humans.

Original languageEnglish (US)
Pages (from-to)2263-2265
Number of pages3
JournalCarcinogenesis
Volume16
Issue number9
StatePublished - 1995

Fingerprint

Oligonucleotides
Benzo(a)pyrene
Pyrene
Enzyme-linked Immunosorbent Assay
Immune Sera
DNA
Reactivity
Oligomers
Specificity
Affine transformation
DNA Adducts
Guanosine
Environmental Monitoring
Human
Enzyme-Linked Immunosorbent Assay
Assays
Enzymes
Enzyme-linked immunosorbent assay
Guanine
Adenine

ASJC Scopus subject areas

  • Cancer Research
  • Physiology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Behavioral Neuroscience

Cite this

Determination of stereospecificity of benzo[a]pyrene diolepoxide-DNA antisera with site-specifically modified oligonucleotides. / Hsu, T. M.; Liu, T. M.; Amin, S.; Geacintov, Nicholas; Santella, R. M.

In: Carcinogenesis, Vol. 16, No. 9, 1995, p. 2263-2265.

Research output: Contribution to journalArticle

@article{9082b1cb73204635a2948fcd670f36ae,
title = "Determination of stereospecificity of benzo[a]pyrene diolepoxide-DNA antisera with site-specifically modified oligonucleotides",
abstract = "Antisera developed against benzo[a]pyrene diolepoxide (BPDE)-DNA adducts are sensitive tools for detection of DNA adducts in human samples. All antisera currently used for biomonitoring studies were produced against DNA or guanosine modified with racemic anti-BPDE. Using a non-competitive enzyme-linked immunosorbent assay (ELISA). Venkatachalam and Wani recently tested polyclonal and monoclonal (5D2) antisera for cross-reactivity against oligonucleotides containing (+)- and (-)-trans-anti-BPDE-N 2-guanine or N 6-adenine adducts and showed different stereospecificity for the two antisera. Because of the importance of antiserum specificity in human biomonitoring studies, we have tested several monoclonal (Mab 5D11 and 5D2) and polyclonal (Pab No 29) antisera developed against racemic anti-BPDE-DNA adducts, and Mab 8E11 developed against anti-BPDE-guanosine adducts. Stereoisomeric anti-BPDE-modified oligonucleotide adducts in the sequence 5'-d(CC-AT-CG(*)CTACC)-3' where G(*) = anti-BPDE-N 2-dG with (+)-trans, (-)-trans, (+)-cis and (-)-cis adduct stereochemistry at the C10 position of anti-BPDE were tested by competitive ELISA. Two structurally related 5-methylchrysene diolepoxide adducts with G(*) = (+)- and (-)-trans-anti-5-MeCDE-N 2-dG in the same oligonucleotide were also tested. While Mab5D2 had the highest affinity for the (-)-trans-anti-BPDE-modified oligomer, Mab 5D11 and 8E11 and Pab No 29 recognized the(+)-trans-anti-BPDE-modified oligomer better than the (-)-trans-anti-BPDE modified oligomer. Mab 5D11 and Pab No 29 recognized racemic anti-BPDE-modified DNA adducts better than trans-anti-BPDE-modifled oligonucleotides; however, Mab 8E11 showed similar sensitivity to racemic anti-BPDE-DNA adducts and (+)-and (-)-trans-anti-BPDE-modified oligomers. All antisera exhibited lower reactivities with both 5-MeCDE modified oligomers. Because of their sensitive detection of (+)-trans-anti-BPDE-dG adducts, the primary adduct produced in vivo, Mab 8E11 and 5D11 and Pab No 29 are appropriate for measurement of most adducts formed in humans.",
author = "Hsu, {T. M.} and Liu, {T. M.} and S. Amin and Nicholas Geacintov and Santella, {R. M.}",
year = "1995",
language = "English (US)",
volume = "16",
pages = "2263--2265",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Determination of stereospecificity of benzo[a]pyrene diolepoxide-DNA antisera with site-specifically modified oligonucleotides

AU - Hsu, T. M.

AU - Liu, T. M.

AU - Amin, S.

AU - Geacintov, Nicholas

AU - Santella, R. M.

PY - 1995

Y1 - 1995

N2 - Antisera developed against benzo[a]pyrene diolepoxide (BPDE)-DNA adducts are sensitive tools for detection of DNA adducts in human samples. All antisera currently used for biomonitoring studies were produced against DNA or guanosine modified with racemic anti-BPDE. Using a non-competitive enzyme-linked immunosorbent assay (ELISA). Venkatachalam and Wani recently tested polyclonal and monoclonal (5D2) antisera for cross-reactivity against oligonucleotides containing (+)- and (-)-trans-anti-BPDE-N 2-guanine or N 6-adenine adducts and showed different stereospecificity for the two antisera. Because of the importance of antiserum specificity in human biomonitoring studies, we have tested several monoclonal (Mab 5D11 and 5D2) and polyclonal (Pab No 29) antisera developed against racemic anti-BPDE-DNA adducts, and Mab 8E11 developed against anti-BPDE-guanosine adducts. Stereoisomeric anti-BPDE-modified oligonucleotide adducts in the sequence 5'-d(CC-AT-CG(*)CTACC)-3' where G(*) = anti-BPDE-N 2-dG with (+)-trans, (-)-trans, (+)-cis and (-)-cis adduct stereochemistry at the C10 position of anti-BPDE were tested by competitive ELISA. Two structurally related 5-methylchrysene diolepoxide adducts with G(*) = (+)- and (-)-trans-anti-5-MeCDE-N 2-dG in the same oligonucleotide were also tested. While Mab5D2 had the highest affinity for the (-)-trans-anti-BPDE-modified oligomer, Mab 5D11 and 8E11 and Pab No 29 recognized the(+)-trans-anti-BPDE-modified oligomer better than the (-)-trans-anti-BPDE modified oligomer. Mab 5D11 and Pab No 29 recognized racemic anti-BPDE-modified DNA adducts better than trans-anti-BPDE-modifled oligonucleotides; however, Mab 8E11 showed similar sensitivity to racemic anti-BPDE-DNA adducts and (+)-and (-)-trans-anti-BPDE-modified oligomers. All antisera exhibited lower reactivities with both 5-MeCDE modified oligomers. Because of their sensitive detection of (+)-trans-anti-BPDE-dG adducts, the primary adduct produced in vivo, Mab 8E11 and 5D11 and Pab No 29 are appropriate for measurement of most adducts formed in humans.

AB - Antisera developed against benzo[a]pyrene diolepoxide (BPDE)-DNA adducts are sensitive tools for detection of DNA adducts in human samples. All antisera currently used for biomonitoring studies were produced against DNA or guanosine modified with racemic anti-BPDE. Using a non-competitive enzyme-linked immunosorbent assay (ELISA). Venkatachalam and Wani recently tested polyclonal and monoclonal (5D2) antisera for cross-reactivity against oligonucleotides containing (+)- and (-)-trans-anti-BPDE-N 2-guanine or N 6-adenine adducts and showed different stereospecificity for the two antisera. Because of the importance of antiserum specificity in human biomonitoring studies, we have tested several monoclonal (Mab 5D11 and 5D2) and polyclonal (Pab No 29) antisera developed against racemic anti-BPDE-DNA adducts, and Mab 8E11 developed against anti-BPDE-guanosine adducts. Stereoisomeric anti-BPDE-modified oligonucleotide adducts in the sequence 5'-d(CC-AT-CG(*)CTACC)-3' where G(*) = anti-BPDE-N 2-dG with (+)-trans, (-)-trans, (+)-cis and (-)-cis adduct stereochemistry at the C10 position of anti-BPDE were tested by competitive ELISA. Two structurally related 5-methylchrysene diolepoxide adducts with G(*) = (+)- and (-)-trans-anti-5-MeCDE-N 2-dG in the same oligonucleotide were also tested. While Mab5D2 had the highest affinity for the (-)-trans-anti-BPDE-modified oligomer, Mab 5D11 and 8E11 and Pab No 29 recognized the(+)-trans-anti-BPDE-modified oligomer better than the (-)-trans-anti-BPDE modified oligomer. Mab 5D11 and Pab No 29 recognized racemic anti-BPDE-modified DNA adducts better than trans-anti-BPDE-modifled oligonucleotides; however, Mab 8E11 showed similar sensitivity to racemic anti-BPDE-DNA adducts and (+)-and (-)-trans-anti-BPDE-modified oligomers. All antisera exhibited lower reactivities with both 5-MeCDE modified oligomers. Because of their sensitive detection of (+)-trans-anti-BPDE-dG adducts, the primary adduct produced in vivo, Mab 8E11 and 5D11 and Pab No 29 are appropriate for measurement of most adducts formed in humans.

UR - http://www.scopus.com/inward/record.url?scp=0029071283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029071283&partnerID=8YFLogxK

M3 - Article

C2 - 7554088

AN - SCOPUS:0029071283

VL - 16

SP - 2263

EP - 2265

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 9

ER -